+1234567890
contact@domain.com
We are Open 08.00am-10.00pm
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech that has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix. In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn's inventories of leronlimab are building up, whether they will ever be being used is actually an open question.


While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last few shares of mine. My first CytoDyn article, "CytoDyn: What In order to Do When It is Too Good to be able to Be True?", set out what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire employment interview which I came away with a bad opinion of the business.

Irony of irony, the bad opinion of mine of the company has grown steadily, although the disappointment hasn't been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today's payment of $3.5 million transfers ownership of this expertise and connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 zillion) as well as the first new drug application approval ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn's helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and many indications, it has this individual remedy as well as a "broad pipeline of indications" as it puts it. I call certain pipelines, "pipedots." In CytoDyn's situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple illness types, multiple publications in addition to multiple presentations.

Might all of it be smoke and mirrors? That's a question I've been asking myself with the very start of the interest of mine in this particular organization. Judging by the multiples of thousands of diverse commentary on listings accessible via Seeking Alpha's CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or possibly some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *